Department of Internal Medicine, Center for Rheumatic Diseases, Dohgo Spa Hospital, 21-21 Otsu Dohgo-Himezuka, Matsuyama, Ehime, 790-0858, Japan.
Mod Rheumatol. 2011 Apr;21(2):215-8. doi: 10.1007/s10165-010-0365-8. Epub 2010 Oct 8.
We report successful tocilizumab (TCZ) use in a patient with adult-onset Still's disease (AOSD) complicated by chronic hepatitis B (CHB) and AA amyloidosis (AAA). Treatments with corticosteroid and various types of immunosuppressants were unsuccessful. Aggravation of CHB ensued, and entecavir was started. Normalisation of liver function and hepatitis B virus (HBV) DNA were confirmed. TCZ was then started. His arthritis and AAA improved dramatically. TCZ is an excellent treatment for refractory AOSD and is feasible in an HBV-infected patient.
我们报告了一例成功使用托珠单抗(TCZ)治疗成人Still 病(AOSD)合并慢性乙型肝炎(CHB)和 AA 淀粉样变性(AAA)的病例。患者曾接受皮质类固醇和各种类型的免疫抑制剂治疗,但均无效。随后 CHB 加重,开始使用恩替卡韦。肝功能和乙型肝炎病毒(HBV)DNA 均恢复正常。随后开始使用 TCZ。他的关节炎和 AAA 显著改善。TCZ 是治疗难治性 AOSD 的有效药物,在 HBV 感染患者中也是可行的。